Ocular Therapeutix Reports $66 Million in Cash, Cash Equivalents

August 11, 2017: By Jon Swedien

Ocular Therapeutix logoOcular Therapeutix’ cash, cash equivalents, and marketable securities totaled $66 million at the end of Q2-2017, the Bedford, Massachusetts, company announced Aug. 8.

Cash used in operating activities was $11.3 million in Q2-2017, compared with $9.8 million in Q2-2016, Ocular Therapeutix said. Total costs and operating expenses for Q2-2017 were $18.8 million, compared with $11.5 million in Q2-2016, the company said.

Ocular Therapeutix reported a net loss of approximately $18.7 million in Q2-2017, compared with a net loss of $11.4 million in Q2-2016. The Q2-2017 results include $2.1 million in non-cash charges for stock-based compensation and depreciation, compared with $1.7 million in such non-cash charges in Q2-2016.

The company is working to obtain approval for its lead product candidate, Dextenza, a proposed treatment for pain after ophthalmic surgery.

In mid-July, Ocular Therapeutix received a complete response letter (CRL) from the US FDA for its resubmitted new drug application (NDA) for Dextenza due to deficiencies in manufacturing and testing.

It was Dextenza’s second CRL related to plant issues.

Ocular Therapeutix made $400 thousand in revenues during Q2-2017 from product sales of ReSure Sealant, a product indicated for prevention of postoperative fluid egress from incisions with a demonstrated wound leak following cataract surgery.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Imprimis Offers Compounded Alternative to Restasis for Dry Eye

US District Court Invalidates Four Restasis Patents

BioTime Prices $25 Million Public Offering of Common Stock

Gemini Completes $42.5 Million Series A Financing for Dry AMD Treatment

BIOPHYTIS Raises €10.4 Million to Develop Anti-Aging Drugs, One for Dry AMD

Amydis Receives $530 Thousand NIH Award to Advance Ophthalmic Diagnostic Probes

Realm Announces Completion of $26 million Private Placement

Sight Sciences Secures $10 Million in Oversubscribed Series C Financing

Aerpio Names Stephen Hoffman CEO; Founder Joseph Gardner Remains President

FDA Advisory Panel Recommends Aerie’s Rhopressa for Glaucoma Patients

FDA Panel Unanimously Backs Spark’s Luxturna as Retinal Gene Therapy

PanOptica Secures $11 Million to Advance Topical Anti-VEGF Eye Drop for Neovascular AMD

Nicox and pSivida to Collaborate to Develop a Sustained Release Drug to Lower IOP

Azura Nets $16 Million in Series B Funding for Dry Eye Treatment

Alcon’s AcrySof Intraocular Lens Reaches 100 Million Implants

Notal Vision’s ForeseeHome Reaches Milestone of 3 Million Tests

FDA to Review Spark’s Retinal Gene Therapy Candidate Oct. 12

Alcon’s AutonoMe IOL Injector Gains CE Mark Approval

Shire Sues Allergan, Claiming Bundling Tactics Block Restasis Competitors

Allergan Decries ‘Unfair’ Patent Challenge Process as US House Launches Probe of Tribe Deal

Coming soon

2017 Refractive Surgery Report: A Global Market Analysis for 2016 to 2022